Sugammadex
شوگامادکس
🧪 VariousSelective reversal agent for rocuronium/vecuronium
Market / country: 🇺🇸 USA
Bridion (US)
🧮 Dose calculator
Reversal of neuromuscular blockade · Regimen source: FDA Bridion · 2.2
- • Based on actual body weight; timing and dose by TOF monitoring; single bolus. FDA Bridion · 2.1
Enter age and weight.
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity to sugammadex (anaphylaxis has occurred without prior exposure). FDA Bridion · 4
Warnings
- • Anaphylaxis; marked bradycardia; reduces hormonal contraceptive effect (backup method for 7 days). FDA Bridion · 5
Formulations
- 100 mg/mL (200 mg/2 mL, 500 mg/5 mL) — injection 🇺🇸 USA FDA Bridion · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Bridion · 8.1
“Risk Summary There are no clinical trial data on BRIDION use in pregnant women to inform any drug-associated risks.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Bridion · 8.2
“Risk Summary No data are available regarding the presence of sugammadex in human milk, the effects of sugammadex on the breast fed infant, or the effects of sugammadex on milk production.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Bridion · 8.4
“The safety and effectiveness of BRIDION for reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide have been established in pediatric patients from birth and older.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Bridion · 8.5
“Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Use in Specific Populations (8.6) , Clinical Pharmacology (12.3) ] .”
- ⚥ Females & males of reproductive potentialUse with caution
Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Bridion · 8.3
“Contraception Upon administration of BRIDION, the efficacy of hormonal contraceptives may be reduced for up to 7 days.”
🔗 Reference links
- FDA (approval record)NDA022225
- DailyMed (FDA label)FDA Bridion
- MedlinePlus (NIH)Sugammadex Injection
- WHO ATC/DDDV03AB35
- Darooyab (Iran)Sugammadex
🇮🇷 Registered in Iran Darooyab · G-5406/Sugammadex
Dosage forms with Iranian generic codes, per Darooyab.
- 51961 · SUGAMMADEX (AS SODIUM) INJECTION, SOLUTION PARENTERAL 100 mg/1mL 2 mL · محلول تزریقی سوگاممادکس (معادل سدیم) ۱۰۰ میلیگرم / ۱ میلیلیتر ۲ میلیلیتر
- 52300 · SUGAMMADEX (AS SODIUM) INJECTION, SOLUTION PARENTERAL 100 mg/1mL 5 mL · محلول تزریقی سوگاممادکس (معادل سدیم) ۱۰۰ میلیگرم / ۱ میلیلیتر ۵ میلیلیتر
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Bridion · 3FDA Bridion · 2.2FDA Bridion · 2.1FDA Bridion · 4FDA Bridion · 5FDA Bridion · SPL approval / marketing categoryFDA Bridion · 8.1FDA Bridion · 8.2FDA Bridion · 8.4FDA Bridion · 8.5FDA Bridion · 8.3
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-5406/Sugammadex
- Clinical review⚠ Unverified